Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effect of Mizagliflozin on Hypoglycemia in Patients With Post-Bariatric Hypoglycemia
Sponsor: Vogenx, Inc.
Summary
VGX-001-013 (EMERGE) is a Phase 2b study to evaluate an investigational new drug, mizagliflozin, for safety, tolerability and its ability to prevent low blood sugar in patients with post-bariatric hypoglycemia.
Official title: Phase 2B Randomized, Placebo-Controlled, Double-Blind, Repeat Dose Parallel Study in Participants With Post-Bariatric Hypoglycemia to Determine the Effect of Mizagliflozin on Hypoglycemia
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
36
Start Date
2026-10
Completion Date
2028-01
Last Updated
2026-08-12
Healthy Volunteers
No
Conditions
Interventions
Mizagliflozin 5 mg
5mg mizagliflozin capsules orally administered TID for 28 days
Mizagliflozin 10 mg
10mg mizagliflozin capsules orally administered TID for 28 days
Placebo
Placebo capsules orally administered TID for 28 days